THE USAGE EVALUATION OF DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN A LOCAL HOSPITAL OF TAIWAN
- At: 2015 FIP Congress in Düsseldorf (Germany)
- Type: Poster
- By: CHANG, Hsiu-Mei (Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, pharmacy department, Kaohsiung City, China Taiwan)
- Co-author(s): Hsiu-Mei Chang
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is orally used in diabetes. It was approved by FDA in 2006 to control blood sugar in patients with type-2 diabetes mellitus (T2DM). The usage has gradually increased since 2010 started in our hospital.Due to its high cost, Sitagliptin has become the second highest annual cost of oral medication.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.